Disappointing results from phase 3 CheckMate 73L study of concurrent nivolumab + chemoradiation for stage III NSCLC & nivol +/- ipilimumab vs durvalumab consolidation. No improvement in PFS over standard PACIFIC approach. Similar to negative PACIFIC-2.

news.bms.com/news/corporate…

☀️Lazy Sunday Lung Cancer Quiz No 7⃣:

What is the rate of Infusion-related reactions with subcutaneous amivantamab reported so far?

The OncoAlert🚨ROUND UP
Covering May 2-8, 2024

👇👇👇

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

⭐️Sharing our editorial 👉Rationalizing rules for immunotherapy combination trials: About time for precision immunotherapy Aakash Desai, MD, MPH OncoAlert ACS Journal Cancer American Cancer Society
acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

InForm, by a mile, the most user-unfriendly trials software known to mankind. Password requirements also more demanding than my bank.

Sense of doom receiving email asking me to login (entailing inevitable failed reset password attempts).

🤬

Saturday, June 1, 7pm CDT at #ASCO24 - join Drs. Benjamin Levy JessicaJLinMD Solange Peters and me for a free comprehensive #CME symposium on targeted therapy in NSCLC. We cover it all in 90min! Register now, live/virtual:

peerview.com/2024Biomarkers [peerview.com]

Every once in a while as an editor you run into a paper that starts out as a pile of straw but with consideration and discussion to help the authors revise it it turns into pure gold. Days like these I love my job!

Had a great time and insightful discussions at #RomeLung24 reviewing biomarkers for #ICI efficacy in #NSCLC . w/ a stellar faculty Jordi Remon Solange Peters Francesco Christian Rolfo, Tony Mok Stephen V Liu, MD, Fred R. Hirsch Federico Cappuzzo Roberto Ferrara Benjamin Besse &

Dr. Enriqueta Felip discusses the role of ADCs in early stage NSCLC at #RomeLung24 but stresses caution in the curative setting. High bar with regard to toxicity and cannot compromise surgery. Potentially for escalation with those who do not achieve pCR?

An elegant presentation by Stephen V Liu, MD regarding synergy between immunotherapy and ADCs which could change lung cancer option’s treatment. #InnovativeCancerTherapies #RomeLung24

Nice session of presentations and discussions this morning at #RomeLung24 on lung cancer IO and ADCs…impressive number of KOLs to discuss and exchange...so many questions about strategies for our patients !

Great overview of resistance mechanisms to #KRAS inhibitors in #NSCLC at #RomeLung24 by AmbrogioLab. Different therapeutic vulnerabilities depending on whether resistance is intrinsic, acquired, or adaptive.

Dr. Solange Peters at #RomeLung24 with a dynamic discussion of next generation checkpoint inhibitors. Beyond PDL1, many disappointments but the future is bright with novel targets and elegant bispecific antibodies.

Important effort to out in Nature Communications characterizing FAK-YAP signaling as mediator of residual disease during targeted therapies in #NSCLC .

✅FAK-YAP inhibition + targeted therapy 💊 combo suppresses residual drug-tolerant cells.
🚨🚨OncoAlert #LCSM
shorturl.at/aexAO

Dr. Ugo Pastorino at #RomeLung24 discusses the impact, importance, unrealized potential of lung cancer screening. Stage migration, improving mortality - but overall low detection rate and low adherence to guidelines. Future: liquid biopsy? Pts without smoking history? Duration?

Dr. Marina Garassino discusses adjuvant alectinib in resected #ALK NSCLC at #RomeLung24 . Profound benefit and our standard of care even but some questions: what will OS impact be? Should we also give chemotherapy? What impact does variant have? Is 2 years enough?

Dr. Tina Cascone at #RomeLung24 gives a brilliant perspective on neoadjuvant vs adjuvant immunotherapy approaches. The neoadjuvant approach allows for tremendous translational study to inform the field. In clinic now, PDL1 informs likelihood of benefit.

#RomeLung24

Tony Mok presents key insights on neoadj chemoIO & goes back to basics to chart a path forward:

- which pts don’t benefit? PDL1<1%, KRAS/STK11, non PR
- how do we measure benefit? MPR, pathCR similar
- will MRD refine tx? Platform will matter

@oncoalert #LCSM

Dr. Tony Mok at #RomeLung24 discusses what to do for patients who do not achieve pCR to neoadjuvant chemo-immunotherapy. Empiric strategies both overtreat and undertreat - we need to follow the science and deliver treatment only where it makes a difference.

Dr. Mariano Provencio proposes a new three musketeers for early stage NSCLC at #RomeLung24 with Drs. Tina Cascone Jonathan Spicer MD PhD Patrick Forde M.Provencio Federico Cappuzzo